Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US.
作者信息
Jazowski Shelley A, Vaidya Avi U, Donohue Julie M, Dusetzina Stacie B, Sachs Rachel E
机构信息
Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.
出版信息
JAMA Intern Med. 2023 Jul 1;183(7):737-739. doi: 10.1001/jamainternmed.2023.0777.
Abstract
摘要
相似文献
1
Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US.
JAMA Intern Med. 2023 Jul 1;183(7):737-739. doi: 10.1001/jamainternmed.2023.0777.
2
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.
JAMA Oncol. 2023 Apr 1;9(4):567-569. doi: 10.1001/jamaoncol.2022.7770.
3
Cancer drugs speed to accelerated approvals, then hit the brakes in timely, clinically beneficial confirmatory trials.
Am J Manag Care. 2024 Aug;30(9 Spec No.):SP722-SP724. doi: 10.37765/ajmc.2024.89597.
4
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
BMJ. 2021 Sep 8;374:n1959. doi: 10.1136/bmj.n1959.
5
US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
JAMA Netw Open. 2022 Sep 1;5(9):e2230973. doi: 10.1001/jamanetworkopen.2022.30973.
6
Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular Approval.
Ther Innov Regul Sci. 2024 Mar;58(2):387-394. doi: 10.1007/s43441-023-00607-0. Epub 2024 Jan 4.
7
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
J Clin Oncol. 2009 Sep 10;27(26):4398-405. doi: 10.1200/JCO.2008.21.1961. Epub 2009 Jul 27.
8
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6.
9
Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish.
JAMA. 2003 Jun 25;289(24):3227-9. doi: 10.1001/jama.289.24.3227.
10
Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Eur J Clin Pharmacol. 2019 Sep;75(9):1193-1200. doi: 10.1007/s00228-019-02695-0. Epub 2019 May 25.
引用本文的文献
1
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study.
EClinicalMedicine. 2025 May 31;84:103088. doi: 10.1016/j.eclinm.2025.103088. eCollection 2025 Jun.
2
Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA.
JAMA Netw Open. 2025 Mar 3;8(3):e252026. doi: 10.1001/jamanetworkopen.2025.2026.
3
The high costs of anticancer therapies in the USA: challenges, opportunities and progress.
Nat Rev Clin Oncol. 2024 Dec;21(12):888-899. doi: 10.1038/s41571-024-00948-1. Epub 2024 Oct 4.
4
Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China.
Heliyon. 2024 Jul 30;10(15):e35454. doi: 10.1016/j.heliyon.2024.e35454. eCollection 2024 Aug 15.
Zotero 插件